<DOC> 
<DOCNO>1040817_business_story_3633220.utf8</DOCNO> 
<TEXT> 

The Telegraph - Calcutta : Business
 Tuesday, August 17, 2004 				 Nicholas inks deal with French firm
 OUR SPECIAL CORRESPONDENT 																								Mumbai, Aug. 16: Nicholas Piramal India Ltd (NPIL) today announced that it has completed a product-licensing agreement with Ethypharm of France for the Indian market.																								Under this pact, Nicholas Piramal will use Ethypharms technology to manufacture dispersible paracetamol tablets for pain relief and fever, particularly for paediatric use, the company informed stock exchanges today.																								According to NPIL, the agreement will further augment its presence in pain-relief and paediatric-care segments. Some of the companys leading paediatric brands include Phenergan, Kidpred, Omnatax and Tixylix.																								Senior officials of NPIL said the agreement with Ethypharm is for a period of five years. The agreement would enable Nicholas Piramal expand its portfolio, which is considered necessary after the new patent regime comes into operation next year, they added.																								Sources said the company already has five such in-licensing deals in operation. There is a separate team at NPIL looking at the possibility of sewing similar deals. 																								NPIL had recently concluded a similar agreement with Genzyme Corporation, USA, for synvisc viscose supplementation for the domestic market. The deal, signed for a period of five years, is expected to increase the companys presence in orthopaedic treatment.																								Synvisc is used for the treatment of pain associated with osteoarthritis in the knee. It is a pill-free treatment that is injected directly into the knee. The product has global sales of $250 million.																								NPIL has a diverse portfolio of branded formulations, vitamins, active pharmaceutical ingredients and diagnostics. It posted a topline sales of Rs 1,270 crore for the year ended March 31, 2004. In the therapeutic category, the company is present in antibiotics, analgesic, antiseptics, central nervous system, dermatology, gastro-enteritis, gynaecology and oncology among others.
</TEXT> 
</DOC>